{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:24:50Z","timestamp":1795011890235,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jhep.2021.10.029","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:18:13Z","timestamp":1636975093000},"page":"536-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"title":["Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study"],"prefix":"10.1016","volume":"76","author":[{"given":"Mary E.","family":"Rinella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4706-682X","authenticated-orcid":false,"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bonacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Trylesinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macky","family":"Natha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Shringarpure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Granston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.10.029_bib1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.029_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818811508","article-title":"Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis","volume":"11","author":"Sayiner","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.029_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.029_bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2021.10.029_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cld.2015.10.008","article-title":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease","volume":"20","author":"Hannah","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2021.10.029_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.029_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.029_bib11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.029_bib12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.029_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.10.029_bib14","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2021.10.029_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jhep.2021.10.029_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.10.029_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2021.10.029_bib18","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.029_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-6-6","article-title":"Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Ratziu","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.029_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphar.2016.00159","article-title":"Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy?","volume":"7","author":"Chin","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2021.10.029_bib21","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2021.10.029_bib22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.10.029_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.029_bib24","first-page":"218","article-title":"Non-invasive assessment of liver fibrosis","volume":"25","author":"Papastergiou","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2021.10.029_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib26","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib27","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.029_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/liv.12896","article-title":"The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease","volume":"36","author":"Irvine","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.10.029_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib31","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhep.2021.10.029_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/2050640619865133","article-title":"Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease","volume":"7","author":"Staufer","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2021.10.029_bib33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/MEG.0000000000000409","article-title":"Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Dincses","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.26030","article-title":"Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"57","author":"Tanwar","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.10.029_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib37","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.10.029_bib38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.10.029_bib39","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating\u00a0the safety and efficacy of obeticholic acid in patients with\u00a0fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2021.10.029_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.7863\/ultra.34.3.403","article-title":"Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography (FibroScan)","volume":"34","author":"Meng","year":"2015","journal-title":"J\u00a0Ultrasound Med"},{"key":"10.1016\/j.jhep.2021.10.029_bib41","series-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Guidance for industry","first-page":"2018","year":"2018"},{"key":"10.1016\/j.jhep.2021.10.029_bib42","series-title":"Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","year":"2018"},{"key":"10.1016\/j.jhep.2021.10.029_bib43","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.10.029_bib44","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/liv.13974","article-title":"Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis","volume":"39","author":"Chalasani","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.10.029_bib45","series-title":"Noninvasive tests (NITs) for hepatic fibrosis in fatty liver syndrome","first-page":"10","author":"Han","year":"2020"},{"key":"10.1016\/j.jhep.2021.10.029_bib46","series-title":"Noninvasive assessment of hepatic fibrosis: overview of serologic and radiographic tests","author":"Curry","year":"2021"},{"key":"10.1016\/j.jhep.2021.10.029_bib47","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10620-019-05886-y","article-title":"Noninvasive measurements predict liver fibrosis well in hepatitis C virus patients after direct-acting antiviral therapy","volume":"65","author":"Huang","year":"2020","journal-title":"Dig Dis Sci"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:18Z","timestamp":1759174998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821021772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0168827821021772"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}